Abstract
Objective: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has been rolled out across Europe for the treatment of Cystic Fibrosis (CF). These new therapies have a predominately positive effect on people with CF (pwCF), improving lung function, weight and reducing pulmonary exacerbations. However, immunogenic reactions to CFTR modulators can occur and may lead to drug discontinuation. We aimed to assess the frequency and severity of these reactions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
